Efficacy and economic evaluation of a volume-based cathflo activase protocol versus a fixed-dose alteplase protocol for catheter occlusions in pediatric patients
| Autor: | Allison M. Chung, Jennifer A. Gilarde, Sheryl Falkos, Rosa Vidal |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Protocol (science)
medicine.medical_specialty business.industry medicine.medical_treatment Fixed dose Surgery Catheter Cathflo activase Pediatrics Perinatology and Child Health Economic evaluation medicine Pharmacology (medical) Dosing Clinical Investigation Prospective cohort study business Central venous catheter |
| Zdroj: | The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. 11(4) |
| ISSN: | 1551-6776 |
| Popis: | OBJECTIVES This prospective study evaluated the efficacy and economic benefit of Cathflo Activase and a volume-dependent protocol versus a previously utilized fixed-dose 2 mg/mL alteplase aliquot protocol for central venous catheter clearance in pediatric patients. METHODS All pediatric patients with a medically diagnosed catheter occlusion were eligible for inclusion into this study. Retrospective data was analyzed from an approved data collection form, which had been implemented during the utilization of the alteplase protocol. Data collection indicators included catheter type, dose, dwell time, outcome of attempt (successful or unsuccessful), additional measures taken, and comments. A new protocol utilizing Cathflo Activase and manufacturer recommended volume-based dosing was prospectively implemented and data was collected and evaluated and compared to data from the alteplase protocol. RESULTS Alteplase and Cathflo protocol data was evaluated for a total of 96 courses in 48 patients (0.09 – 22.8 years, 2.15 – 105.2 kg). Complete resolution was achieved in 69.6% of patients with the alteplase protocol, partial resolution was attained in 8.7%, and treatment failure occurred in 21.7% of patients. For the Cathflo Activase group, complete resolution was observed in 82% of occlusions, with 8% partial resolution and treatment failure of 10%. The average cost per dose utilized by our patients during this study was $49.68 and $30.56 for the alteplase and Cathflo Activase groups, respectively. CONCLUSIONS Our data indicate that the Cathflo Activase protocol may be as efficacious as the previous alteplase protocol. Furthermore, there are added time and cost benefits. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|